Saturday 17 October 2026
Export TRAW’s income statement to Excel — free account
Traws Pharma, Inc.
TRAW Healthcare Biotechnology
Traws Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, up 1,134.5% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 1.78% and free cash flow fell 25.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.37
0.03
−7.50%
Follow TRAW
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 1.20 | — |
+8 more quarters Free account |
P/S ratio |
— | — | 3.27 | — | |
P/FCF ratio |
— | — | 0.00 | — | |
P/Operating CF |
— | — | (3.37) | — | |
P/B ratio |
— | — | 0.00 | — | |
Price to Tangible BV |
— | — | 0.00 | — | |
EV/Sales |
— | — | 1.92 | — | |
EV/EBITDA |
— | — | 0.00 | — | |
EV/Operating CF |
— | — | (0.30) | — | |
EV/FCF |
— | — | (0.30) | — | |
Quick Ratio |
0.87 | 0.36 | 0.68 | 1.07 | |
Current Ratio |
0.93 | 0.43 | 0.72 | 1.22 | |
Net Debt/EBITDA |
1.60 | 0.45 | 0.52 | 1.59 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.16 | 0.00 | |
Operating CF/Net income |
2.87 | 0.45 | 0.61 | 1.32 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (172.33) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.21 | 0.30 | 0.24 | 0.21 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
— | — | (0.35) | — | |
Graham Number |
— | — | 0.00 | — | |
Earnings Yield |
— | — | 83.43% | — | |
Free Cash Flow Yield |
— | — | (195.73%) | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.47) | (0.24) | (0.34) | (0.45) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.29) | |
Free Cash Flow per Share |
(0.47) | (0.24) | (0.34) | (0.75) | |
Cash per Share |
0.32 | 0.29 | 0.46 | 0.73 | |
Shareholders Equity per Share |
0.11 | (0.50) | (0.08) | 0.52 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.11 | (0.50) | (0.08) | 0.52 | |
Free Cash Flow |
(7.50) | (2.58) | (2.76) | (6.60) | |
Working Capital |
(0.71) | (7.54) | (3.17) | 1.74 | |
Capital Expenditures |
— | — | 0.00 | (2.58) | |
Net Current Asset Value |
(0.76) | (7.80) | (3.27) | 1.73 | |
EV/EBIT |
— | — | 0.00 | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | — | |
| Other line items | |||||
Average Receivables |
2.39 | 1.67 | 2.78 | 2.06 | |
Average Payables |
5.55 | 7.66 | 6.92 | 5.29 | |
Average Assets |
13.55 | 13.61 | 17.79 | 10.69 | |
Average Common Equity |
4.98 | 0.34 | (16.13) | 1.26 |
Columns are period end dates